Longeveron Announces Additional Analysis For Phase 2a Clinical Trial Of Mild Alzheimer's Disease Stem Cell Therapy Laromestrocel Accepted For Poster Presentation At 2026 AAIC July 12-15
Benzinga Newsdesk 4 months ago
News
Poster Presentation (Exhibit Hall) Date:Monday, July 13, 2026Time:7:30am – 4:15pm BSTSession:In-Person Posters Tuesday; Drug Development: HumanTopic:Laromestrocel in Mild Alzheimer's Disease: Additional Phase 2a
| Poster Presentation (Exhibit Hall) | |
| Date: | Monday, July 13, 2026 |
| Time: | 7:30am – 4:15pm BST |
| Session: | In-Person Posters Tuesday; Drug Development: Human |
| Topic: | Laromestrocel in Mild Alzheimer's Disease: Additional Phase 2a Clinical Data Analysis |
Results from the CLEAR MIND Phase 2a clinical trial, which support the therapeutic potential of laromestrocel in the treatment of mild Alzheimer's disease and provided evidence-based support for further clinical development, were published in the peer-reviewed journal Nature Medicine in March 2025.